Check out our latest #whitepaper containing clinical trial data, real-world evidence, and example algorithms that detail how T2Candida can be incorporated into practice and improve care for invasive candidiasis in your own practice.
- March 31, 2023
Our T2 Magnetic Resonance (T2MR) technology platform can detect pathogens, biomarkers and other abnormalities in a broad range of unpurified sample types, including whole blood, plasma, serum, saliva, sputum and urine. With limits of detection as low as 1 CFU/mL, T2MR has the potential for numerous additional applications beyond our current pipeline.
T2 Biosystems is selectively establishing alliances with dynamic organizations that have the capability and desire to develop additional breakthrough applications utilizing our T2MR platform. Partnership opportunities for co-development and commercialization include our current products as well as potential new applications for T2MR, ranging from companion diagnostics to research as well as non-healthcare applications.
We continue to pursue a strategic partnership for the commercial development of the T2Lyme™ Panel as an LDT.
Interested in discussing additional breakthrough applications utilizing our T2MR technology?